Periinterventional Management of Edoxaban in Major Procedures: Results from the DRESDEN NOAC REGISTRY
Christina Köhler,
Luise Tittl,
Ulrike Hänsel,
Evelyn Hammermüller,
Sandra Marten,
Christiane Naue,
Marianne Spindler,
Laura Stannek,
Kristina Fache,
Jan Beyer-Westendorf
Affiliations
Christina Köhler
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Luise Tittl
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Ulrike Hänsel
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Evelyn Hammermüller
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Sandra Marten
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Christiane Naue
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Marianne Spindler
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Laura Stannek
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Kristina Fache
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Jan Beyer-Westendorf
Division of “Thrombosis and Hemostasis,” Department of Medicine I, University Hospital “Carl Gustav Carus,” Technical University Dresden, Dresden, Germany
Background Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism (VTE) treatment or stroke prevention in atrial fibrillation. Major surgical procedures are not uncommon in anticoagulated patients but data on perioperative edoxaban management are scarce.
